

## Appendix 4D

Omni Bridgeway Limited (“OBL”, “the Company” or “the Parent”)

ABN 45 067 298 088

### Half year ended 31 December 2023

#### Results for announcement to the market

Current reporting period: Half year ended 31 December 2023

Previous reporting period: Half year ended 31 December 2022

	Up/Down	Percentage Change	\$'000
Revenue from ordinary activities	Up	42%	15,629
Loss from ordinary activities after tax attributable to members	Down	(11)%	(47,627)
Net loss for the period attributable to members	Down	(11)%	(47,627)
Other comprehensive loss after tax for the period	Down	(239)%	(10,806)
Total comprehensive income after tax for the period	Up	201%	22,551

#### Dividends

The Directors have determined not to pay a dividend for the period ended 31 December 2023 to equity holders of the parent company.

The Directors did not pay a final dividend for the financial year ended 30 June 2023.

The Directors have determined they will consider, and where appropriate, implement, a regular semi-annual dividend which reflects the cash position and performance of the Company at the time of the dividend and the likely demand for cash over the ensuing 12 month period. The Company has put in place a dividend reinvestment plan and, on appropriate occasions, will arrange underwriting to reduce the impact a particular dividend might otherwise have on cash.

#### Net tangible assets per ordinary share

	31-Dec-23	30-Jun-23
	\$	\$
Basic net tangible assets per ordinary share <sup>1</sup>	0.98	0.68
Basic net assets per ordinary share	2.91	2.89
Book value of investments per ordinary share	1.78	1.99

1. Net tangible assets excludes intangible assets - litigation contracts in progress, goodwill, claims portfolio and contract assets.

## Entities over which control was gained or lost during the period

The Company has lost control over the following existing entities during the period.

	Percentage Lost	
	Country of Establishment	At 31-Dec-23
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20

The Company has established the following entities during the period.

	Percentage Owned	
	Country of Establishment	At 31-Dec-23
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20
Omni Bridgeway (Fund 4) S2 L.P.	USA	20
Omni Bridgeway (Fund 8) Delaware SPV LLC	USA	81
Omni Bridgeway (Fund 8) Guernsey SPV Limited	Guernsey	81
Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 1	USA	81
Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 2	USA	81
Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 3	USA	81

## Associates

The Company has the following associates during the period:

	Percentage Owned	
	Country of Incorporation	At 31-Dec-23
OB Capital Cooperatief UA	Netherlands	5
Omni Bridgeway (Fund 1) LLC	USA	100
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20

## Foreign operations

In compiling this report International Financial Reporting Standards have been used as the basis of preparation for all foreign operations.

## Explanation of results

The attached Interim Financial Report for the half year ended 31 December 2023 forms part of this document. This Interim Financial Report is to be read in conjunction with the most recent annual financial report. A copy of the 2023 annual financial report and other documents are available on the website at [www.omnibridgeway.com](http://www.omnibridgeway.com) or on the ASX website at [www.asx.com.au](http://www.asx.com.au).

## Review opinion

The review opinion of the Company's auditors, BDO, is attached to the financial statements.

  
Guillaume Leger

Global Chief Financial Officer

Date: 28 February 2024

For personal use only

**Interim Financial Report**  
Half year ended 31 December 2023

# Omni Bridgeway Limited

ABN 45 067 298 088

## Interim Financial Report

for the half year ended 31 December 2023

### Contents

Directors' Report	5
Notes to the Directors' Report	9
Auditor's Independence Declaration	10
Interim Consolidated Statement of Comprehensive Income	11
Interim Consolidated Statement of Financial Position	12
Interim Consolidated Statement of Cash Flows	13
Interim Consolidated Statement of Changes in Equity	14
Notes to the Interim Consolidated Financial Statements	15
Directors' Declaration	39
Independent Review Report	40
Corporate Information	42
Glossary	43

# Interim Financial Report

## for the half year ended 31 December 2023

### Directors' Report

The Directors present their report (referred to hereafter as the "Interim Financial Report"), together with the financial statements, on the consolidated entity (referred to hereafter as the "consolidated entity" or "the Group") consisting of Omni Bridgeway Limited (referred to hereafter as "OBL", "the Company" or "the Parent") and the entities it controlled at the end of, or during, the half year ended 31 December 2023.

#### Directors

The names of the Company's Directors in office during the half year ended 31 December 2023 and until the date of this report are as below. Unless stated otherwise, the Directors were in office for this entire period.

Michael Kay	Non-Executive Chairman
Andrew Saker	Managing Director & CEO (retired 26 October 2023)
Raymond van Hulst	Managing Director & CEO (appointed 26 October 2023), former Executive Director and Co-Chief Investment Officer – EMEA
Michael Green	Non-Executive Director
Karen Phin	Non-Executive Director
Christine Feldmanis	Non-Executive Director

### Review and results of operations

#### Highlights for the half year ended 31 December 2023

##### Operational highlights<sup>1</sup>

- US\$485 million<sup>2</sup> first close of Fund 4 and Fund 5 series II capital raise on improved cost coverage terms.
- €135 million first tranche of debt capital raised for our €300 million Fund 8, focused on global enforcement investments.
- Significant expansion of our capabilities in the UK, the world's second largest litigation finance market.
- Investment income of \$235.7 million, including income yet to be recognised, with \$50.1 million provisionally attributable to OBL.
- 12 full completions, 6 partial completions, and a secondary market transaction achieving an overall MOIC of 2.4x, and an IRR of 55%.
- US\$21.5 million cash proceeds from the sale of a 25% interest in a portfolio of 15 intellectual property (IP) investments in Fund 4.
- \$260 million of new investment commitments with 38% improved pricing on FY23.
- \$182 million strong pipeline of new investment opportunities representing a further 29% of our commitments target for the year ending 30 June 2024.
- Possible investment completions with an estimated portfolio value (**EPV**) of \$5.1 billion over the next 12 months (rolling period).
- Total cash and receivables of \$291.2 million; OBL only cash and receivables of \$122.4 million (\$80.9 million in OBL balance sheet cash and \$40.1 million of OBL share of cash and receivables within Funds), plus \$60 million in undrawn debt.

##### Financial highlights<sup>3</sup>

- Total income of \$135.8 million (including a net gain on deconsolidation of the Fund 4 IP portfolio) derived from diversified sources comprising litigation completions, a secondary market sale, management fees, and interest revenue.
- Group profit after tax (before non-controlling interests (**NCI**)) of \$33.4 million (1H23: \$30.1 million loss after tax); with \$47.6 million loss attributable to OBL (the Group's equity holders) and \$81.0 million profit attributable to NCI.
- Employee expenses of \$34.4 million decreased 12% due to team optimisation, a reduction in contractors and higher capitalised costs of investment managers.
- Corporate overheads of \$9.0 million increased 4% due mainly to the amortisation of the Fund 8 insurance premium, notwithstanding significant reductions in other corporate overhead expenses.
- Carrying value of litigation investments of \$654.7 million (30 June 2023: \$596.7 million) across 285 funded litigation investments. Negative case developments including lower than anticipated income, extended duration and adverse milestones associated with a funded law firm portfolio have resulted in a \$44.9 million reduction of the carrying value.

<sup>1</sup> Represents non-IFRS information. Here Fund 5 is presented at 100% for consistency of presentation across OBL's Funds.

<sup>2</sup> Inclusive of OBL's co-funding (OBL's commitment of US\$100 million to each Series II fund is capped at 20% of the ultimate fund size (i.e. after further closings).

<sup>3</sup> Per the Group Consolidated Financial Statements.

# Interim Financial Report

## for the half year ended 31 December 2023

### Directors' Report (continued)

#### Review and results of operations (continued)

#### Commitments<sup>4</sup>


The Group's geographic and asset diversification assists in mitigating the risk of any increased competition or regulatory intervention arising in any one region. New commitments are the investment into future income streams and enable the Group to achieve economies of scale to diversify risk and provide superior risk adjusted returns in this asset class.

The stated target for the year ending 30 June 2024 includes \$625 million in new commitments or equivalent value, prioritising value over volume to reflect potential for improved pricing on new commitments.

New commitments of \$259.8 million were made in period ending 31 December 2023 with approximately 38% higher pricing compared to FY23, based on the NPV of loss-adjusted probability-weighted investment cashflows per dollar of new commitments for the total portfolio.

This accounts for 42% of the full year commitment goal and compares to an average 47% of commitment target reached as at 31 December over the last three years. On an equivalent value basis, due to improved pricing, this accounts for 58% of the full year value generation goal.

An additional 29 exclusive term sheets have been agreed, representing approximately \$182 million in investment opportunities, which if converted into funded investments is a further 29% of our commitment target for the year ending 30 June 2024.



#### Portfolio review<sup>2</sup>

In December 2023, in conjunction with the development of probabilistic models for the transition to fair value, we undertook a thorough review of methodology and key assumptions underpinning quantum and duration estimates for all investments. This also allowed us to review the historic possible completion period (PCP) and estimated portfolio value (EPV) slippage by benchmarking the probabilistic model assumptions against the EPV and PCP.

Although neither method is necessarily more accurate on a case-by-case basis given the inherent uncertainties of litigation, we have revised EPV and PCP estimates for the portfolio. Completions are inherently uncertain and beyond our control, and investments may still complete as per prior EPV and PCP estimates.

While the revisions led to a combination of positive and negative EPV adjustments, the overall impact was a reduction in EPV of \$1.3 billion at 31 December 2023 compared to 30 September 2023.

The EPV (including conditionally funded and investment committee (IC) approved investments) at 31 December 2023 is \$27.6 billion, down 10% compared to 30 September 2023. Excluding the secondary market disposal, EPV was 8% lower compared to 30 September 2023.

<sup>4</sup> Represents non-IFRS information. Here Fund 5 is presented at 100% for consistency of presentation across OBL's Funds.

# Interim Financial Report

## for the half year ended 31 December 2023

### Directors' Report (continued)

#### Review and results of operations (continued)

In line with the indicated changed disclosures on EPV, included in our 2Q24 Investment Portfolio Report dated 25 January 2023, we no longer report EPV with PCP for specific financial years.

This is replaced by an EPV of \$5.1 billion which is assessed to possibly complete in the 12 months following the end of the quarter. This 12-month rolling EPV is based on investments which are subject to various stages of (anticipated) settlement discussions or for which an award or a judgment is expected. All or only part of these may actually complete during the 12 month period. This approach better reflects the timing risk associated with investment completions, which are determined by the courts as well as the litigation and resolution approach of claimants and defendants, neither of which we control or can accurately predict. This also aligns with our legal finance peers, none of whom provide such information in their disclosures.

At 31 December 2023, there were 314 investments (30 June 2023: 301) in the Group's total portfolio, including 29 conditionally funded and IC approved investments.

#### EPV profile<sup>5,6</sup>

\$ million	#	Average duration	Possible EPV completion in the next 12 months	Total EPV
Balance sheet	5	8.8 yrs	5	106
Funds 2&3	21	4.6 yrs	1,533	3,097
Fund 4 <sup>7</sup>	45	1.6 yrs	1,183	7,588
Fund 5	70	1.7 yrs	1,631	9,976
Fund 6	141	7.9 yrs	736	3,600
Fund 8 <sup>8</sup>	3	0.6 yrs	-	81
Total funded investments	285	5.1 yrs	5,088	24,448
Conditionally funded investments	10			1,394
IC approved investments	19			1,787
Total all investments	314			27,629

#### Secondary market

The Group continues to utilise secondary market sales as a risk management strategy to reduce duration and completion risks, while enhancing liquidity and internal rates of return. In December 2023, we completed the sale of a 25% interest in a portfolio of 15 intellectual property (IP) investments (**Investments**) in Fund 4 for initial cash proceeds of US\$21.5 million, representing a multiple on invested capital (**MOIC**) of 2.0x of the apportioned aggregated deployments to date. The purchaser will receive a preferred return on its deployments alongside OBL, beyond which OBL retains further profit rights on the 25% interest.

Upon completion of the sale, each of the investments were treated as partial completions in our fund and performance reporting, the Fund 4 IP portfolio was deconsolidated and resulted in a net gain before non-controlling interests (**NCI**) of approximately US\$51.0 million EBITDA (after NCI of approximately US\$4.6 million EBITDA) before management and performance fees. The EPV relating to the 75% retained interest of the Investments is reflected in the Fund 4 EPV profile. The residual interest in the Investments is recognised as "Litigation Investments - investment in associates" within the Group Consolidated Financial Statements.

#### Fund capital raising

The US\$485 million first close of the Fund 4 and Fund 5 series II capital raising (**Series II**) completed in December 2023 on improved cost coverage terms. The continued and additional investment by existing investors together with OBL's co-funding provides a strong base to market the remaining US\$515 million capacity of Series II.

Series II has been structured to improve the cost coverage by OBL as manager through the inclusion of transaction fees payable on investments. Transaction fees, comparable to facility fees in traditional lending, are targeted to average around 2.5% to 3.0% of investment commitments and will typically be payable to OBL in the first years of an investment's life cycle. The transaction fees represent a significant improvement on the fee terms of the first series, in line with our stated objective to increase cost coverage contribution from future funds.

<sup>5</sup> Represents non-IFRS information. Here Fund 5 is presented at 100% for consistency of presentation across OBL's Funds.

<sup>6</sup> Further information on terms, including definitions of key concepts, used in the table above is detailed at the end of the Directors' Report and available in our Glossary at <https://omnibridgeway.com/investors/omni-bridgeway-glossary> and Notes at <https://omnibridgeway.com/investors/notes-to-quarterly-reports> and should be read in conjunction with this report.

<sup>7</sup> The IP portfolio in Fund 4 was deconsolidated on 8 December 2023 following the sale of a 25% interest in these investments. The EPV relating to the 75% retained interest of the IP portfolio is included. The residual interest of the IP portfolio in Fund 4 is recognised as an investment in associate in the Group Consolidated Financial Statements.

<sup>8</sup> Including investments transferred from the warehouse and investments currently anticipated being transferred.

# Interim Financial Report

## for the half year ended 31 December 2023

### Directors' Report (continued)

#### Review and results of operations (continued)

In September 2023, the first €135 million tranche of debt was raised for our €300 million Fund 8, focused on global enforcement investments. Capital loss in Fund 8 is insured pursuant to a principal protection insurance indemnity of an initial amount of €135 million. The insurance policy has an option to extend the indemnity to €270 million, which provides for a second series or an upsize of series one. Omni Bridgeway has committed an initial €15 million standby equity and can increase to €30 million when the insurance uplift option is exercised. The Fund 8 insurance premium and establishment costs, previously paid by OBL on behalf of the fund were received as a \$10.3 million cash reimbursement to OBL during the period ending 31 December 2023.

#### Board and management

On 26 October 2023, Raymond van Hulst was appointed Managing Director and Chief Executive Officer (CEO) of the Group following the retirement of Andrew Saker, after more than eight years in the role.

Mr van Hulst, former Executive Director and Co-Chief Investment Officer of EMEA, previously held a wide range of senior roles in the Company having been a key member of the legacy Omni Bridgeway team for over 20 years, and brings a breadth of experience in legal firms. Since the merger of IMF Bentham and Omni Bridgeway Holding B.V in 2019, Mr van Hulst has focused on the globalisation of the enforcement investment strategy and integration of the businesses. His experience provides business continuity and a smooth transition.

#### Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the half year ended 31 December 2023.

#### Dividends

The Directors have determined not to pay a dividend for the period ended 31 December 2023 to equity holders of the parent company. The Directors did not pay a final dividend for the financial year ended 30 June 2023.

#### Rounding

The amounts contained within this report have been rounded to the nearest \$1,000 or \$100,000 (where rounding is applicable) under the option available to the Company under ASIC Corporations (Rounding in Financial/Director's Reports) Instrument 2022/519.

#### Subsequent events after reporting date


In January 2024, we received a positive appeal decision relating to a Fund 4 investment, and in February 2024, we reached settlement in two Fund 5 investments for which we anticipate recognising, in aggregate, approximately \$29 million of income in by 30 June 2024.

Except as disclosed in this report there have been no other subsequent events after the reporting date that are not included in the Group Consolidated Financial Statements.

#### Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Signed in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.



Michael Kay  
Non-Executive Chairman

Date: 28/02/24



# Interim Financial Report

## for the half year ended 31 December 2023

### Notes to the Directors' Report

#### Further information

Certain terms used throughout the Directors' Report including, but not limited to, investment income, fee revenue, estimated portfolio value (**EPV**), commitments and fair value (**FV**) are presented as non-IFRS information.

Commitments, EPV and FV include conditional and Investment Committee approved investments. The investments of Funds 2&3, Fund 4, Fund 6 and Fund 8 are consolidated within the Group Consolidated Financial Statements, along with the interest of the respective external Fund investors if applicable.

Fund 1 was deconsolidated on 31 May 2023. The associated EPV, effective from that date, is excluded from this document.

The Fund 4 IP portfolio was deconsolidated on 8 December 2023 following the sale of a 25% interest in these investments. The EPV relating to the 75% retained interest is proportionally reflected in the Fund 4 EPV profile.

Fund 1 and Fund 5 are not consolidated within the Group Consolidated Financial Statements; the residual interest in Fund 1 and in the Fund 4 IP portfolio is recognised as an investment in associate, whereas Fund 5 is brought in at the Group's attributable 20% share of income, assets, and liabilities.

Throughout the Directors' Report, Fund 5 is presented at 100% values (except where otherwise stated) for consistency of presentation across OBL's funds.

Where investments are co-funded with an entity which is not affiliated with Omni Bridgeway, the co-funded proportion of the applicable investment is excluded from the Directors' Report (except where otherwise stated).

Further information on the terms, including definitions of key concepts, is available in our Glossary at <https://omnibridgeway.com/investors/omni-bridgeway-glossary> and Notes at <https://omnibridgeway.com/investors/notes-to-quarterly-reports> and should be read in conjunction with this report.

**DECLARATION OF INDEPENDENCE BY GLYN O'BRIEN TO THE DIRECTORS OF OMNI BRIDGEWAY LIMITED**

As lead auditor for the review of Omni Bridgeway Limited for the half-year ended 31 December 2023, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Omni Bridgeway Limited and the entities it controlled during the period.



**Glyn O'Brien**  
**Director**

**BDO Audit (WA) Pty Ltd**  
Perth  
28 February 2024

For personal use only

# Interim Consolidated Statement of Comprehensive Income

## for the half year ended 31 December 2023

	Notes	Consolidated	
		31-Dec-23 \$'000	31-Dec-22 \$'000
<b>Continuing operations</b>			
Revenue from contracts with customers	2	12,229	5,997
Interest revenue	3	3,400	5,027
Net gain on derecognition of litigation investments - intangible assets	4	45,613	1,195
Net loss on disposal of litigation investments - purchased claims	10	(82)	-
Net gain on deconsolidation of subsidiaries	12	73,149	6,376
Other income		1,528	971
<b>Total income</b>		<b>135,837</b>	<b>19,566</b>
Finance costs	5(a)	462	2,636
Amortisation of litigation investments - claims portfolio	5(b)	4,045	2,727
Depreciation expense	5(c)	2,200	1,950
Employee benefits expense	5(d)	34,359	39,033
Corporate and office expense	5(e)	9,007	8,635
Other expenses	5(f)	8,614	5,575
Impairment expense and adverse costs - litigation investments	5(g)	38,444	3,725
Share of net loss/(profit) in associates	12	8,213	(1,337)
<b>Profit/(Loss) before tax and fair value adjustments</b>		<b>30,493</b>	<b>(43,378)</b>
Fair value adjustments on financial liabilities		982	(21)
<b>Profit/(Loss) before tax</b>		<b>31,475</b>	<b>(43,399)</b>
Income tax benefit	6	(1,882)	(13,263)
<b>Profit/(Loss) for the period</b>		<b>33,357</b>	<b>(30,136)</b>
<b>Attributable to:</b>			
Equity holders of the Parent	7	(47,627)	(42,793)
Non-controlling interests		80,984	12,657
		<b>33,357</b>	<b>(30,136)</b>
<b>Other comprehensive income/(loss)</b>			
Items that may be subsequently reclassified to profit and loss:			
Movement in foreign currency translation reserve		(5,034)	9,574
Items that will not be subsequently reclassified to profit and loss:			
Movement in foreign currency translation reserve attributed to non-controlling interests		(5,772)	(1,806)
Other comprehensive (loss)/income for the period, net of tax		(10,806)	7,768
<b>Total comprehensive income/(loss) for the period</b>		<b>22,551</b>	<b>(22,368)</b>
<b>Attributable to:</b>			
Equity holders of the Parent		(52,661)	(33,219)
Non-controlling interests		75,212	10,851
<b>Loss per share attributed to the ordinary equity holders of the Company (cents per share)</b>			
Basic loss per share (cents per share)	7	(17.02)	(15.76)
Diluted loss per share (cents per share)	7	(17.02)	(15.76)

The above Interim Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying notes.

# Interim Consolidated Statement of Financial Position

as at 31 December 2023

	Notes	Consolidated	
		31-Dec-23 \$'000	30-Jun-23 \$'000
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	14	132,846	117,016
Trade and other receivables	17	103,989	140,770
Contract costs		939	939
Other assets	18	10,118	8,000
Income tax receivable		1,213	-
<b>Total current assets</b>		<b>249,105</b>	<b>266,725</b>
<b>Non-current assets</b>			
Trade and other receivables	17	43,049	45,661
Litigation investments - claims portfolio	9	131,300	125,775
Litigation investments - purchased claims	10	47,444	37,423
Litigation investments - intangible assets	11	305,154	370,085
Litigation investments - financial assets		13,895	7,078
Litigation investments - investment in associates	12	156,948	56,336
Goodwill		102,062	103,304
Right of use assets and other plant and equipment		17,916	18,446
Investment in associates	12	7,433	6,981
Contract costs		1,174	1,644
Other assets	18	14,426	17,788
Deferred tax assets	6	87,795	77,589
<b>Total non-current assets</b>		<b>928,596</b>	<b>868,110</b>
<b>Total assets</b>		<b>1,177,701</b>	<b>1,134,835</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		48,041	50,110
Income tax payable		-	8,007
Provisions	20	31,327	31,238
Lease liabilities		3,570	2,933
Litigation investment - deferred consideration		7,172	3,342
Other financial liabilities	19	10,444	8,097
<b>Total current liabilities</b>		<b>100,554</b>	<b>103,727</b>
<b>Non-current liabilities</b>			
Provisions	20	1,137	1,291
Lease liabilities		14,281	15,008
Borrowings	15	192,065	181,639
Litigation investment - deferred consideration		1,039	4,325
Deferred income tax liabilities		43,938	30,879
Other financial liabilities	19	2,053	10,750
Other liabilities		8,050	2,930
<b>Total non-current liabilities</b>		<b>262,563</b>	<b>246,822</b>
<b>Total liabilities</b>		<b>363,117</b>	<b>350,549</b>
<b>Net assets</b>		<b>814,584</b>	<b>784,286</b>
<b>Equity</b>			
Contributed equity	16	462,253	449,854
Reserves		(2,274)	18,488
Accumulated losses		(167,118)	(119,491)
<b>Equity attributable to equity holders of the parent</b>		<b>292,861</b>	<b>348,851</b>
Non-controlling interests	23	521,723	435,435
<b>Total equity</b>		<b>814,584</b>	<b>784,286</b>

The above Interim Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

## Interim Consolidated Statement of Cash Flows for the half year ended 31 December 2023

	Notes	Consolidated	
		31-Dec-23 \$'000	31-Dec-22 \$'000
<b>Cash flows from operating activities</b>			
Proceeds from litigation investments - claims portfolio		2,886	3,435
Payments for litigation investments - claims portfolio		(10,978)	(6,858)
Proceeds from management and performance fees		8,656	6,626
Payments to suppliers and employees		(43,191)	(63,150)
Interest income		1,201	721
Interest paid		(10,963)	(5,436)
Income tax paid		(8,958)	(2,318)
<b>Net cash flows used in operating activities</b>		<b>(61,347)</b>	<b>(66,980)</b>
<b>Cash flows from investing activities</b>			
Proceeds from litigation investments - purchased claims		1,034	-
Payments for litigation investments - purchased claims		(12,432)	-
Proceeds from litigation investments - intangible assets		139,026	104,211
Payments for litigation investments - intangible assets		(87,004)	(83,360)
Payments for litigation investments - capitalised overhead and employee costs		(4,867)	(3,528)
Payments for plant and equipment		(28)	(521)
Loans from/(to) related parties		249	(943)
Proceeds from sale of interest in litigation investments	23	31,708	-
<b>Net cash flows from investing activities</b>		<b>67,686</b>	<b>15,859</b>
<b>Cash flows from financing activities</b>			
Payments of costs for issuing debt		-	(9,037)
Repayment of bonds and notes		-	(149,440)
Drawdown of debt facility	15	-	150,000
Drawdown of debt - Fund 8	15	10,071	-
Payments of lease liabilities		(2,384)	(2,131)
Contributions from non-controlling interests	23	62,022	58,447
Distributions to non-controlling interests	23	(58,782)	(42,982)
<b>Net cash flows from financing activities</b>		<b>10,927</b>	<b>4,857</b>
Net increase/(decrease) in cash and cash equivalents held		17,266	(46,264)
Net foreign exchange difference		(1,436)	34
Cash and cash equivalents at beginning of period		117,016	158,966
<b>Cash and cash equivalents at end of period</b>	14	<b>132,846</b>	<b>112,736</b>

The above Interim Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

# Interim Consolidated Statement of Changes in Equity

for the half year ended 31 December 2023

	Issued capital	Share based payments reserve	Foreign currency translation reserve	Option premium reserve	Convertible note reserve	Fund equity reserve	Retained earnings/ (accumulated losses)	Total	Non-controlling interest	Total equity
Consolidated	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<b>As at 1 July 2023</b>	<b>449,854</b>	<b>22,742</b>	<b>(5,913)</b>	<b>3,404</b>	<b>3,832</b>	<b>(5,577)</b>	<b>(119,491)</b>	<b>348,851</b>	<b>435,435</b>	<b>784,286</b>
Profit/(Loss) for the period	-	-	-	-	-	-	(47,627)	(47,627)	80,984	33,357
Other comprehensive loss	-	-	(5,034)	-	-	-	-	(5,034)	(5,772)	(10,806)
<b>Total comprehensive income/(loss) for the period</b>	<b>-</b>	<b>-</b>	<b>(5,034)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(47,627)</b>	<b>(52,661)</b>	<b>75,212</b>	<b>22,551</b>
<b>Equity transactions:</b>										
Shares issued	12,399	(12,430)	-	-	-	-	-	(31)	-	(31)
Share based payments, net of tax	-	4,236	-	-	-	-	-	4,236	-	4,236
Shares issued to settle deferred and variable deferred consideration	-	-	-	-	-	-	-	-	-	-
Contributions from non-controlling interests	-	-	-	-	-	-	-	-	62,022	62,022
Distributions to non-controlling interests	-	-	-	-	-	-	-	-	(58,782)	(58,782)
Share Buy-back Scheme	-	-	-	-	-	-	-	-	-	-
Deconsolidation of Subsidiary	-	-	-	-	-	-	-	-	-	-
Changes in the proportion of equity held by non-controlling interests	-	-	(5,772)	-	-	(1,762)	-	(7,534)	7,836	302
<b>As at 31 December 2023</b>	<b>462,253</b>	<b>14,548</b>	<b>(16,719)</b>	<b>3,404</b>	<b>3,832</b>	<b>(7,339)</b>	<b>(167,118)</b>	<b>292,861</b>	<b>521,723</b>	<b>814,584</b>
	Issued capital	Share based payments reserve	Foreign currency translation reserve	Option premium reserve	Convertible note reserve	Fund equity reserve	Retained earnings/ (accumulated losses)	Total	Non-controlling interest	Total equity
Consolidated	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<b>As at 1 July 2022</b>	<b>406,963</b>	<b>32,273</b>	<b>(19,806)</b>	<b>3,404</b>	<b>3,832</b>	<b>(9,944)</b>	<b>(87,832)</b>	<b>328,890</b>	<b>410,609</b>	<b>739,499</b>
Profit/(Loss) for the period	-	-	-	-	-	-	(42,793)	(42,793)	12,657	(30,136)
Other comprehensive income/(loss)	-	-	9,574	-	-	-	-	9,574	(1,806)	7,768
<b>Total comprehensive income/(loss) for the period</b>	<b>-</b>	<b>-</b>	<b>9,574</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(42,793)</b>	<b>(33,219)</b>	<b>10,851</b>	<b>(22,368)</b>
<b>Equity transactions:</b>										
Shares issued	13,746	(19,399)	-	-	-	-	-	(5,653)	-	(5,653)
Share based payments, net of tax	-	5,997	-	-	-	-	-	5,997	-	5,997
Shares issued to settle deferred and variable deferred consideration	30,712	-	-	-	-	-	-	30,712	-	30,712
Contributions from non-controlling interests	-	-	-	-	-	-	-	-	58,447	58,447
Distributions to non-controlling interests	-	-	-	-	-	-	-	-	(70,976)	(70,976)
Share Buy-back Scheme	(286)	-	-	-	-	-	-	(286)	-	(286)
Deconsolidation of Subsidiary	-	-	-	-	-	-	-	-	(57,690)	(57,690)
Changes in the proportion of equity held by non-controlling interests	-	-	-	-	-	(6,778)	-	(6,778)	6,779	1
<b>As at 31 December 2022</b>	<b>451,135</b>	<b>18,871</b>	<b>(10,232)</b>	<b>3,404</b>	<b>3,832</b>	<b>(16,722)</b>	<b>(130,625)</b>	<b>319,663</b>	<b>358,020</b>	<b>677,683</b>

The above Interim Statement of Changes in Equity should be read in conjunction with the accompanying notes.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023

### About this report

The interim consolidated financial statements of Omni Bridgeway Limited ("OBL", "the Company" or "the Parent") and its subsidiaries ("the Group" or "consolidated entity") for the half-year ended 31 December 2023 was authorised for issue in accordance with a resolution of the Directors on 28 February 2024. The principal activities of the entities within the consolidated group are:

- (i) the investment into and management of Funds (or Fund-like structures) that are focused on investing into litigation and dispute resolution matters globally; and
- (ii) the continued holding of direct investments into similar litigation and dispute resolution matters.

Omni Bridgeway Limited (ABN 45 067 298 088) is a for profit company incorporated and domiciled in Australia and limited by shares that are publicly traded on the Australian Securities Exchange (ASX code: OBL).

#### a. Basis of preparation

This interim consolidated financial report for the half-year ended 31 December 2023 is a condensed general purpose financial report prepared in accordance with AASB 134 and IAS 34 Interim Financial Reporting. The Group has prepared the financial statements on the basis that it will continue to operate as a going concern. The Directors consider that there are no material uncertainties that may cast significant doubt over this assumption. They have formed a judgment that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and not less than 12 months from the end of the reporting period.

This interim consolidated financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the Group as the annual financial report.

It is recommended that the interim consolidated financial report for the half year be read in conjunction with the annual report for the year ended 30 June 2023 and considered together with any public announcements made by the Company during the half-year ended 31 December 2023 in accordance with the continuous disclosure obligations of the Corporations Act 2001 and the ASX Listing Rules.

The amounts contained within this report have been rounded to the nearest \$1,000 or \$100,000 (where rounding is applicable) under the option available to the Company under ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/91.

#### b. Basis of consolidation

The interim consolidated financial statements comprise the financial statements of Omni Bridgeway Limited and its subsidiaries, as listed in Note 23, at 31 December 2023.

#### c. Presentation currency

For the purpose of the interim consolidated financial statements, the results and the financial position of each entity are expressed in Australian dollars, which is the functional and presentation currency for the Company.

#### d. Significant accounting policies

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2023. All new and amended accounting standards and interpretations effective from 1 July 2023 were adopted by the Group with no material impact.

#### e. New or amended Accounting Standards and Interpretations adopted

Australian accounting standards and interpretations that have recently been issued or amended but are not yet effective have not been adopted by the consolidated entity for the half-year ended 31 December 2023. The Group will assess the impact of these new standards during the reporting period to which they are applicable.

#### f. Significant accounting judgments, estimates and assumptions

The significant accounting judgments, estimates and assumptions that have been applied in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2023.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### A. RESULTS FOR THE HALF-YEAR

#### Note 1: Segment Information

The Group only operates in one industry, being funding and provision of services in relation to dispute resolution. For management purposes, the Group is organised into operating segments comprising the OBL Group's corporate operations and the Group's fund structures.

The OBL Group's wholly owned subsidiaries own historical litigation in progress investments and provide investment management advisory and administration services to the Group's fund structures in the following locations:

- Australia
- United States
- Canada
- Asia
- New Zealand
- Latin America
- Europe, Middle East and Africa (EMEA)

The Group's Fund structures include:

- **Funds 2 & 3** – This comprises Omni Bridgeway (Fund 2) Pty Ltd and Omni Bridgeway (Fund 3) Pty Ltd and IMF Bentham ROW SPV 1 Limited and IMF Bentham ROW SPV 2 Limited. These entities jointly invest in litigation investments outside the United States. Funds 2&3 are consolidated into the Group.
- **Fund 4** – This Fund invests in litigation investments in the United States. It consists of a series of parallel investing entities comprising Omni Bridgeway (Fund 4) Invt 1 LP; Omni Bridgeway (Fund 4) Invt 2 LP; Omni Bridgeway (Fund 4) Invt 3 LP; Omni Bridgeway (Fund 4) Invt 4 LP; Omni Bridgeway (Fund 4) Invt 5 LP; Omni Bridgeway (Fund 4) Invt 6 LP; Omni Bridgeway (Fund 4) Invt 7 LP; Omni Bridgeway (Fund 4) Invt 8 LP; Omni Bridgeway (Fund 4) Invt 9 LP; Security Finance (Fund 4) LLC; JPV I LP and Omni Bridgeway (Fund 4) S2 LP. Fund 4 entities are consolidated into the Group. On 8 December 2023, the Group completed the sale of a 25% interest in a portfolio of 15 intellectual property (IP) investments in Fund 4 to an affiliate of GLS Capital Partners Fund II, LP for an initial amount of US\$21.5 million, representing a multiple on invested capital (MOIC) of 2.0x of the apportioned aggregated deployments to date.
- **Fund 5** – Consists of a collective investment group comprising Omni Bridgeway (Fund 5) LP, Omni Bridgeway (Fund 5) Cayman Invt. Limited, Omni Bridgeway (Fund 5) Australian Invt Pty Ltd, Omni Bridgeway (Fund 5) Canada Investments Ltd, Omni Bridgeway (Fund 5) NZ Invt Limited, Omni Bridgeway (Fund 5) S2 GP Limited (formerly Omni Bridgeway (Fund 5) Cayman DDI Limited), Omni Bridgeway (Fund 5) S2 Cayman Invt Limited (formerly Gold Road Limited), Oak Henge Limited, Omni Bridgeway (Fund 5) S2 Australian Invt. Pty Ltd, Omni Bridgeway (Fund 5) S2 LP as well as parallel joint investor, Omni Bridgeway (Fund 5) GPA Pty Ltd. This Fund invests in litigation investments outside the United States. Only the parallel joint investor is consolidated within the Group and included in the segment note.
- **Fund 6** – Is an investment structure focused in Europe, Middle East and Africa that was acquired in a business combination on 8 November 2019 and includes the entity responsible for providing the management of Fund 7. It was established to invest in litigation, arbitration and enforcement proceedings, and for the work-out and monetisation of claims. Revenue is derived from enforcement and recovery services and other income is derived from litigation investments. OBL retains control and ownership of Fund 6 via its equity interests. Legal ownership of the litigation investments are spread across the entire OBE Group. Fund 6 is consolidated into the Group.
- **Fund 8** – is an investment structure focused on global enforcement investments and comprises Omni Bridgeway (Fund 8) Guernsey Investments Limited; Omni Bridgeway (Fund 8) Delaware SPV LLC; Omni Bridgeway (Fund 8) Guernsey SPV Limited; Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 1; Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 2; Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 3. Fund 8 is consolidated into the Group.

For Funds 2 & 3, the non-controlling interest is comprised of equity interests which carry an entitlement to receive a capped priority return on drawn capital and a further preferred return on committed but undrawn capital. OBL retains control and ownership of the Funds via its equity interests. Upon satisfaction of the non-controlling interests' priority returns, OBL is entitled to a manager return. After satisfaction of the priority return and the manager returns, the residual net cash flows are to be distributed 80% to OBL and 20% to non-controlling interests. The Funds have an infinite life and all distributions are discretionary.

For Fund 4 the non-controlling interest is comprised of an equity interest which, together with OBL's interest, carries an entitlement to receive return of capital plus a hurdle return on invested capital; and a pro-rata share of any residual after OBL's periodic management fee and transactional based performance fee. OBL retains control and ownership of the Funds via its equity interest. The Fund has an infinite life and all distributions are discretionary.



# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 1: Segment Information (continued)

For Fund 5, there is no non-controlling interest as only OBL's 100% owned investment vehicle is consolidated. OBL's owned vehicle represents 20% of the total Fund 5 structure from which OBL is entitled to periodic management fees and transactional based performance fees.

For Fund 6, the non-controlling interest is comprised of an equity interest which, together with OBL's interest, carries a case by case entitlement to receive return of capital plus a return on invested capital after OBL's transactional based performance fee. OBL retains control and ownership of the Funds via its equity interest. The Fund has an infinite life and all distributions are discretionary during the investment period.

For Fund 8, there is no non-controlling interests as the fund is structured as an insured, leveraged special purpose vehicle (SPV). The capital for the fund is sourced from limited recourse debt.

Inter-segment revenue comprises interest revenue on intercompany loans and advisory fees.

Intercompany interest revenue is recognised in accordance with AASB 9 using the effective interest rate method.

Adjustments and eliminations relate to certain finance and overheads costs that are not allocated to individual segments as the underlying expenses are incurred within wholly owned operations. These costs are capitalised into litigation funding contracts on consolidation of the Group. The associated tax effect accounting for these items is also managed on a Group basis and not allocated to the individual segments.

Inter-segment revenues and expenses are eliminated on consolidation and reflected in the "adjustments and eliminations" column.

Adjustments made in the balance sheet include adjustments to non-current assets to eliminate intercompany loans and investments in subsidiaries on consolidation.

	Group		Funds					Consolidation	
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	8 \$'000	Adjustments and eliminations \$'000	Consolidated \$'000
<b>Segment result for half-year ended 31 December 2023</b>									
Revenue from contracts with customers	7,180	-	-	-	-	3,148	3,452	(1,551)	12,229
Interest revenue on cash and deposits	1,382	-	198	219	4	-	-	-	1,803
Interest revenue on receivables	-	-	406	127	-	(118)	-	-	415
Interest revenue on litigation investments - purchased claims	-	-	1,182	-	-	-	-	-	1,182
Inter-segment	19,324	-	-	-	-	(62)	-	(19,262)	-
<b>Segment revenue</b>	<b>27,886</b>	<b>-</b>	<b>1,786</b>	<b>346</b>	<b>4</b>	<b>2,968</b>	<b>3,452</b>	<b>(20,813)</b>	<b>15,629</b>
Net gain/(loss) on derecognition of litigation investments - intangible assets	(569)	-	2,570	45,788	804	5,905	-	-	54,498
Derecognition of capitalised overheads on litigation investments - intangible assets	-	-	(318)	(8,003)	(564)	-	-	-	(8,885)
Net gain/(loss) on disposal of litigation investments - purchased claims	-	-	-	-	-	(82)	-	-	(82)
Net gain on deconsolidation of subsidiaries	(12,082)	-	-	85,231	-	-	-	-	73,149
Other income	392	-	136	-	-	4	996	-	1,528
<b>Total Income</b>	<b>15,627</b>	<b>-</b>	<b>4,174</b>	<b>123,362</b>	<b>244</b>	<b>8,795</b>	<b>4,448</b>	<b>(20,813)</b>	<b>135,837</b>
Amortisation of litigation investments - claims portfolio	-	-	-	-	-	4,068	(23)	-	4,045
Impairment expense and adverse costs - litigation investments	-	-	6,049	22,549	4,285	5,561	-	-	38,444
Other expenses	77,050	-	31	5,103	1,709	6,916	760	(36,927)	54,642
Share of (profit)/loss in associates	6,026	-	-	2,187	-	-	-	-	8,213
<b>Profit/(Loss) before tax and fair value</b>	<b>(67,449)</b>	<b>-</b>	<b>(1,906)</b>	<b>93,523</b>	<b>(5,750)</b>	<b>(7,750)</b>	<b>3,711</b>	<b>16,114</b>	<b>30,493</b>
Profit/(Loss) on fair value adjustment of financial assets and liabilities	1,076	-	(805)	-	-	-	-	711	982
<b>Profit/(Loss) before tax</b>	<b>(66,373)</b>	<b>-</b>	<b>(2,711)</b>	<b>93,523</b>	<b>(5,750)</b>	<b>(7,750)</b>	<b>3,711</b>	<b>16,825</b>	<b>31,475</b>
Income tax (benefit)/expense	(15,449)	-	(1,192)	(8)	(2,569)	(2,164)	-	19,500	(1,882)
<b>Segment result</b>	<b>(50,924)</b>	<b>-</b>	<b>(1,519)</b>	<b>93,531</b>	<b>(3,181)</b>	<b>(5,586)</b>	<b>3,711</b>	<b>(2,675)</b>	<b>33,357</b>
<b>Attributable to:</b>									
Equity holders of the Parent	(50,924)	-	(1,519)	9,693	(3,181)	(2,732)	3,711	(2,675)	(47,627)
Non-controlling interests	-	-	-	83,838	-	(2,854)	-	-	80,984

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 1: Segment Information (continued)

	Group		Funds					Consolidation	
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	8 \$'000	Adjustments and eliminations \$'000	Consolidated \$'000
<b>Segment assets and liabilities at 31 December 2023</b>									
Cash and cash equivalents <sup>1</sup>	80,852	-	6,004	41,700	-	4,290	-	-	132,846
Receivables due from the completion of litigation investments	1,521	-	36,296	34,486	-	34,660	2,675	-	109,638
Other current assets	45,732	-	2,752	3,750	10,207	20,527	2,419	(34,781)	50,606
Litigation investments - claims portfolio	1	-	-	-	-	126,111	1,460	3,728	131,300
Litigation investments - purchased claims	-	-	14,098	13,819	-	19,527	-	-	47,444
Litigation investments - intangible assets	10,940	-	92,033	113,896	36,183	61,877	-	35,251	350,180
Litigation investments - financial assets	-	-	-	10,318	7,411	-	-	(3,834)	13,895
Litigation investments - investment in associates	38,467	-	-	114,811	-	-	-	3,670	156,948
Litigation investments - provision for impairment	-	-	(5,507)	(30,005)	(1,593)	(3,663)	-	(4,258)	(45,026)
Goodwill	102,062	-	-	-	-	-	-	-	102,062
Investments in funds	261,185	-	-	-	-	28	-	(253,752)	7,461
Other non-current assets	431,789	-	7,087	-	1,061	20	15,078	(334,688)	120,347
<b>Total segment assets</b>	<b>972,549</b>	<b>-</b>	<b>152,763</b>	<b>302,775</b>	<b>53,269</b>	<b>263,377</b>	<b>21,632</b>	<b>(588,664)</b>	<b>1,177,701</b>
Current liabilities	93,736	-	9,732	7,274	53,555	13,347	2,279	(79,369)	100,554
Non-current liabilities	203,048	-	5,625	-	-	14,395	11,502	27,993	262,563
<b>Total segment liabilities</b>	<b>296,784</b>	<b>-</b>	<b>15,357</b>	<b>7,274</b>	<b>53,555</b>	<b>27,742</b>	<b>13,781</b>	<b>(51,376)</b>	<b>363,117</b>
<b>Net assets</b>	<b>675,765</b>	<b>-</b>	<b>137,406</b>	<b>295,501</b>	<b>(286)</b>	<b>235,635</b>	<b>7,851</b>	<b>(537,288)</b>	<b>814,584</b>
<b>Equity attributable to:</b>									
Equity holders of the Parent	675,765	-	28,547	59,100	(286)	63,693	7,851	(541,809)	292,861
Contributed equity - NCI	-	-	85,292	207,019	-	154,240	-	-	446,551
Earnings - NCI	-	-	23,567	29,382	-	17,702	-	4,521	75,172
<b>Total equity</b>	<b>675,765</b>	<b>-</b>	<b>137,406</b>	<b>295,501</b>	<b>(286)</b>	<b>235,635</b>	<b>7,851</b>	<b>(537,288)</b>	<b>814,584</b>

1. Cash in Funds can only be used for litigation investments and expenses within the respective Funds in accordance within their mandates and constituent documents.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 1: Segment Information (continued)

	Group		Funds					Consolidation	
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	8 \$'000	Adjustments and eliminations \$'000	Consolidated \$'000
<b>Segment result for half-year ended 31 December 2022</b>									
Revenue from contracts with customers	2,621	-	-	-	-	3,376	-	-	5,997
Interest revenue on cash and deposits	579	4	147	-	-	-	-	-	730
Interest revenue on receivables	-	-	1,230	-	-	95	-	-	1,325
Interest revenue on litigation investments - purchased claims	-	-	2,104	235	-	633	-	-	2,972
Inter-segment	16,039	-	-	-	-	(153)	-	(15,886)	-
<b>Segment revenue</b>	<b>19,239</b>	<b>4</b>	<b>3,481</b>	<b>235</b>	<b>-</b>	<b>3,951</b>	<b>-</b>	<b>(15,886)</b>	<b>11,024</b>
Net gain/(loss) on derecognition of litigation investments - intangible assets	1,793	(6,781)	1,774	8,585	2,119	1,985	-	-	9,475
Derecognition of capitalised overheads on litigation investments - intangible assets	-	(6,965)	(568)	(547)	(200)	-	-	-	(8,280)
Net gain/(loss) on disposal of litigation investments - purchased claims	-	6,376	-	-	-	-	-	-	6,376
Other income	20	-	951	-	-	-	-	-	971
<b>Total Income</b>	<b>21,052</b>	<b>(7,366)</b>	<b>5,638</b>	<b>8,273</b>	<b>1,919</b>	<b>5,936</b>	<b>-</b>	<b>(15,886)</b>	<b>19,566</b>
Amortisation of litigation investments - claims portfolio	-	-	-	-	-	2,727	-	-	2,727
Impairment expense - litigation	175	(4,759)	3,347	(1,129)	-	1,510	-	-	(856)
Other expenses	78,362	43	3,204	133	348	8,190	44	(27,914)	62,410
Share of (profit) in associates and joint ventures	270	(1,607)	-	-	-	-	-	-	(1,337)
<b>Profit/(Loss) before tax and fair value</b>	<b>(57,755)</b>	<b>(1,043)</b>	<b>(913)</b>	<b>9,269</b>	<b>1,571</b>	<b>(6,491)</b>	<b>(44)</b>	<b>12,028</b>	<b>(43,378)</b>
Profit/(Loss) on fair value adjustment of financial liabilities	(91)	-	295	-	-	-	-	(225)	(21)
<b>Profit/(Loss) before tax</b>	<b>(57,846)</b>	<b>(1,043)</b>	<b>(618)</b>	<b>9,269</b>	<b>1,571</b>	<b>(6,491)</b>	<b>(44)</b>	<b>11,803</b>	<b>(43,399)</b>
Income tax (benefit)/expense	(16,362)	-	469	9	888	431	-	1,302	(13,263)
<b>Segment result</b>	<b>(41,484)</b>	<b>(1,043)</b>	<b>(1,087)</b>	<b>9,260</b>	<b>683</b>	<b>(6,922)</b>	<b>(44)</b>	<b>10,501</b>	<b>(30,136)</b>
<b>Attributable to:</b>									
Equity holders of the Parent	(41,484)	(6,546)	(1,087)	1,448	683	(6,264)	(44)	10,501	(42,793)
Non-controlling interests	-	5,503	-	7,812	-	(658)	-	-	12,657

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 1: Segment Information (continued)

	Group		Funds				Consolidation		
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	8 \$'000	Adjustments and eliminations \$'000	Consolidated \$'000
<b>Segment assets and liabilities at 30 June 2023</b>									
Cash and cash equivalents <sup>1</sup>	92,602	-	14,655	8,175	-	1,566	18	-	<b>117,016</b>
Receivables due from the completion of litigation investments	36,571	-	47,131	17,094	-	44,902	-	-	<b>145,698</b>
Other current assets	13,934	-	7,149	1,609	15,381	22,482	1,051	(12,781)	<b>48,825</b>
Litigation investments - claims portfolio	-	-	-	-	-	122,118	-	3,657	<b>125,775</b>
Litigation investments - purchased claims	-	-	11,751	16,318	-	9,354	-	-	<b>37,423</b>
Litigation investments - intangible assets	9,460	-	81,096	172,763	29,073	64,341	-	29,577	<b>386,310</b>
Litigation investments - financial assets	-	-	-	3,777	7,199	-	-	(3,898)	<b>7,078</b>
Litigation investments - investment in associates	52,559	-	-	-	-	-	-	3,777	<b>56,336</b>
Litigation investments - provision for impairment	-	-	(556)	(11,589)	-	(3,354)	-	(726)	<b>(16,225)</b>
Goodwill	103,304	-	-	-	-	-	-	-	<b>103,304</b>
Investments in funds	257,160	-	-	-	-	30	-	(250,178)	<b>7,012</b>
Other non-current assets	415,427	-	2,551	949	1,670	4,211	12,836	(321,361)	<b>116,283</b>
<b>Total segment assets</b>	<b>981,017</b>	<b>-</b>	<b>163,777</b>	<b>209,096</b>	<b>53,323</b>	<b>265,650</b>	<b>13,905</b>	<b>(551,933)</b>	<b>1,134,835</b>
Current liabilities	58,026	-	15,645	14,695	46,485	15,964	11,468	(58,556)	<b>103,727</b>
Non-current liabilities	212,645	-	5,065	-	522	19,948	2,975	5,667	<b>246,822</b>
<b>Total segment liabilities</b>	<b>270,671</b>	<b>-</b>	<b>20,710</b>	<b>14,695</b>	<b>47,007</b>	<b>35,912</b>	<b>14,443</b>	<b>(52,889)</b>	<b>350,549</b>
<b>Net assets</b>	<b>710,346</b>	<b>-</b>	<b>143,067</b>	<b>194,401</b>	<b>6,316</b>	<b>229,738</b>	<b>(538)</b>	<b>(499,044)</b>	<b>784,286</b>
<b>Equity attributable to:</b>									
Equity holders of the parent	710,346	-	24,750	38,880	6,316	66,946	(538)	(497,849)	<b>348,851</b>
Contributed equity - NCI	-	-	83,968	192,519	-	142,237	-	-	<b>418,724</b>
Earnings - NCI	-	-	34,349	(36,998)	-	20,555	-	(1,195)	<b>16,711</b>
<b>Total equity</b>	<b>710,346</b>	<b>-</b>	<b>143,067</b>	<b>194,401</b>	<b>6,316</b>	<b>229,738</b>	<b>(538)</b>	<b>(499,044)</b>	<b>784,286</b>

1. Cash in Funds can only be used for litigation investments and expenses within the respective Funds in accordance within their mandates and constituent documents.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 2: Revenue from contracts with customers

	Corporate \$'000	Fund 6 \$'000	Fund 8 \$'000	Total \$'000
<b>Half-year ended 31 December 2023</b>				
<b>Type of service</b>				
Litigation investments - claims portfolio <sup>1</sup>	-	3,083	3,452	6,535
Management and service fees <sup>2</sup>	5,629	65	-	5,694
	<b>5,629</b>	<b>3,148</b>	<b>3,452</b>	<b>12,229</b>
<b>Half-year ended 31 December 2022</b>				
<b>Type of service</b>				
Litigation investments - claims portfolio <sup>1</sup>	-	2,534	-	2,534
Management and service fees <sup>2</sup>	2,621	842	-	3,463
	<b>2,621</b>	<b>3,376</b>	<b>-</b>	<b>5,997</b>
<b>Half-year ended 31 December 2023</b>				
<b>Geographical markets</b>				
Europe	-	3,148	3,452	6,600
Australia	3,347	-	-	3,347
United States	1,243	-	-	1,243
Cayman Islands	1,039	-	-	1,039
	<b>5,629</b>	<b>3,148</b>	<b>3,452</b>	<b>12,229</b>
<b>Half-year ended 31 December 2022</b>				
<b>Geographical markets</b>				
Europe	-	3,376	-	3,376
Australia	666	-	-	666
United States	1,354	-	-	1,354
Cayman Islands	601	-	-	601
	<b>2,621</b>	<b>3,376</b>	<b>-</b>	<b>5,997</b>

1. This represents revenue generated from services transferred at a point in time.

2. This represents revenue generated from services transferred over time.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 3: Interest revenue

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
<b>Interest revenue</b>		
Interest revenue on cash and deposits	1,803	730
Interest revenue on receivables	415	1,325
Interest revenue on litigation investments - purchased claims	1,182	2,972
	<b>3,400</b>	<b>5,027</b>

### Note 4: Net gain on derecognition of litigation investments - intangible assets

Net gain on derecognition of litigation investments - intangible assets is derived from the disposal through sale or completion (partial or full) of the underlying litigation that the Group invested in.

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
<b>Net gain on derecognition of litigation investments - intangible assets</b>		
Proceeds	98,308	41,073
Derecognition of carrying cost	(52,695)	(39,878)
	<b>45,613</b>	<b>1,195</b>

Net gain on derecognition of litigation investments - intangible assets can be represented geographically as follows:

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Australia	(1,547)	1,404
United States	37,752	(5,670)
Canada	(210)	(164)
EMEA	6,522	3,455
Asia	3,101	2,125
Latin America	(5)	45
	<b>45,613</b>	<b>1,195</b>

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 5: Expenses

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
<b>(a) Finance costs</b>		
Interest on lease liabilities	220	153
Other finance charges	242	2,483
	<b>462</b>	<b>2,636</b>
<b>(b) Amortisation of litigation investments - claims portfolio</b>		
Amortisation of litigation investments - claims portfolio (Note 9)	4,045	2,727
<b>(c) Depreciation expense</b>		
Depreciation of property, plant & equipment	2,200	1,950
<b>(d) Employee benefits expense</b>		
Wages and salaries	27,309	31,355
Superannuation expense	1,384	1,198
Directors' fees	230	283
Payroll tax	1,729	1,257
Share based payments	3,802	4,893
Long service leave	(95)	47
	<b>34,359</b>	<b>39,033</b>
<b>(e) Corporate and office expense</b>		
Insurance expense	2,571	1,868
Network expense	934	938
Marketing expense	609	894
Occupancy expense	407	312
Professional fee expense	3,499	2,417
Recruitment expense	191	962
Travel expense	796	1,244
	<b>9,007</b>	<b>8,635</b>
<b>(f) Other expenses</b>		
ASX listing fees	63	124
General expenses	826	908
Amortisation of contract costs	470	470
Postage, printing and stationary	760	821
Repairs and maintenance	2	2
Share registry costs	26	6
Staff training, development and conferences	34	531
Net foreign exchange loss	2,328	601
Expected credit loss – receivables	4,105	2,112
	<b>8,614</b>	<b>5,575</b>
<b>(g) Impairment expense and adverse costs - litigation investments</b>		
Adverse costs - litigation investments (Note 20)	1,673	4,581
Net impairment expense/(gain) - litigation investments	36,771	(856)
	<b>38,444</b>	<b>3,725</b>

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 6: Income tax

A reconciliation between tax expense/(benefit) and the product of accounting profit/(loss) before income multiplied by the Group's applicable income tax rate is as follows:

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Accounting profit/(loss) before income tax	31,475	(43,399)
At the Group's statutory income tax rate of 30% (2023: 30%)	9,443	(13,020)
Foreign tax rate adjustments	(1,714)	596
Adjustment in respect of income and deferred tax of previous years	1,287	(261)
Non-assessable income	(10,031)	(3,710)
Non-deductible expenditures	1,304	500
Relating to deductible temporary differences not previously recognised	-	-
Write off of non-recoverable Deferred Tax Assets	153	36
Other	(2,324)	2,596
<b>Income tax expense/(benefit) reported in the Statement of Comprehensive Income</b>	<b>(1,882)</b>	<b>(13,263)</b>

### Unrecognised temporary differences and tax losses

At 31 December 2023, the Group had \$2.1 million (30 June 2023: \$2.5 million) of unrecognised deferred tax assets relating to temporary differences and tax losses in its Canadian subsidiaries.

### Deferred tax assets relating to Australian operations

The deferred tax assets balance includes \$41.9 million (30 June 2023: \$34.3 million) of assets relating to carried forward tax losses of Omni Bridgeway Limited (OBL) tax consolidated group as at 31 December 2023.

It is probable that the OBL tax group will earn sufficient taxable income to utilise the losses as the Australian business has significant investments on balance sheet and through Fund 5 participation, which have a combined EPV of \$10 billion. In addition, OBL is expected to receive distributions from Funds 2&3 and intra group income from the wider group.

### Deferred tax assets relating to USA operations

The deferred tax assets balance includes \$20.4 million (30 June 2023: \$24.7 million) of assets relating to carried forward tax losses of Omni Bridgeway Holdings (USA) Inc. Under existing tax regulations, the losses incurred prior to financial year ended 30 June 2019 can be carried forward for 20 years and losses incurred thereafter can be carried forward indefinitely.

The US business had a history of incurring tax losses before the year ended 31 December 2023. The losses have arisen primarily from the implementation of the expansion of the administrative base in the United States to support strategic growth initiatives that are, according to plan, yet to realise their full value. Omni has considered the utilisation of these tax losses within the expanded US business and has determined that, based on approved budgets and existing case matters, it is probable that the US tax group will earn sufficient taxable income to utilise the losses. Further, in assessing the utilisation of the tax losses, Omni considers there to be convincing other evidence to support the recoverability of these tax losses including:

- (i) The US business has continued to be in an expansion and infrastructure growth phase. Additional costs have been incurred in the business related to the expansion of activity and changes in operations to a Fund management structure. Investments in people, systems and infrastructure have been made ahead of the expected investment activity of the Funds. Fund 4 started in 2019 for an approved portfolio of commitments up to US\$500 million (of which the US business has a 20% interest) is currently in its investment commitment activity phase. With an average investment life of circa 3 years, a significant portion of the expected income is in the future. This income generation will be by way of both investment returns and fee revenues.
- (ii) The US business has raised substantial external capital over the past five years via its Fund structures. Fund 4 investors committed US\$500 million (80% external commitments). The external capital raised is the foundation of the investing activity that enables the US business to grow and generate returns to realise future taxable income. Fund 4 series II has recently launched and has raised A\$485 million from existing investors to date.
- (iii) US business committed a record level of commitments of A\$234 million last year. The commitment group supports the increased business activity, growth phase, profit generation and recovery of deferred tax assets in the future,
- (iv) There are 54 US investments as at 31 December 2023. It has been determined that the income generated by these investments, when realised, will exceed the tax losses within the US business.

Omni Bridgeway (Fund 2) Pty Limited and Omni Bridgeway (Fund 3) Pty Limited carried combined total deferred tax assets balances of \$0.2 million as at 31 December 2023 (30 June 2023: \$0.1 million), the deferred tax assets balances were predominantly related to the loss of Asian and Europe, Middle East & Africa investments during this reporting period. The Funds are 100% committed with litigation investment that are expected to generate significant taxable income in their respective tax jurisdictions in the future.



# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 7: Loss per share

(a) Loss used in calculating loss per share

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
<b>For basic and diluted loss per share</b>		
Total net loss attributable to ordinary equity holders of the Parent	<b>(47,627)</b>	(42,793)

(b) Weighted average number of shares

	Consolidated	
	31-Dec-23	31-Dec-22
	Number	Number
Weighted average number of ordinary shares outstanding	<b>279,826,823</b>	271,493,088
Effect of dilution:		
Performance rights	-	-
Variable deferred consideration shares	-	-
Weighted average number of ordinary shares	<b>279,826,823</b>	271,493,088

Variable deferred consideration is payable by the issue of fully paid ordinary shares in OBL. Please refer to Note 13 and Note 19 for details.

These shares have not been included for tranches of Variable Deferred Consideration where the performance milestones have not been met. In addition to this, the inclusion of any of these shares would be considered anti-dilutive.

During the period to 31 December 2023, the performance milestones for Tranche 4 of the Variable Deferred Consideration have been met. The shares relating to this are only included in dilutive loss per ordinary share where the performance milestones have been met and they do not have an anti-dilutive effect. As at 31 December 2023, there were 7,755,446 variable deferred consideration shares calculated as meeting the performance criteria for inclusion in diluted loss per share, however these were not included due to their anti-dilutive effect.

The weighted average number of ordinary shares outstanding includes performance rights granted under the Long Term Incentive Plan only where the performance hurdles are met as at period end and they do not have an anti-dilutive effect. As at 31 December 2023, there were no performance rights calculated meeting the performance criteria for inclusion in diluted loss per share.

There have been no transactions involving ordinary shares or potential ordinary shares that would significantly change the number of ordinary shares outstanding between the reporting date and the date of completion of these financial statements.

### Note 8: Dividends paid and proposed by Omni Bridgeway Limited (the Parent)

#### Cash dividends on ordinary shares declared and paid

There were no dividends declared or paid for the period ended 31 December 2023 to the equity holders of the parent.

The Company considers all its capital management options in light the cash position and performance of the Group at the time as well as the likely demand for cash over the ensuing 12-month period. In determining the appropriate mechanism to deliver returns to shareholders, the board will consider both semi-annual dividends and share buy-backs. Relevant considerations include the source and nature of income and the prevailing share price relative to the intrinsic value and the franking credit balance.

The Company has a dividend reinvestment plan (DRP) that shareholders may elect to participate in. On appropriate occasions, the Company may arrange DRP underwriting to reduce the impact a particular dividend might otherwise have on the Group's cash resources.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### B. INVESTMENTS AND INTANGIBLE ASSETS

#### Note 9: Litigation investments - claims portfolio

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Balance at start of the period <sup>1</sup>	125,775	106,123
Additions	10,692	20,969
Amortisation of carrying costs <sup>2</sup>	(4,045)	(4,042)
Impairment loss	(1,881)	(719)
Foreign currency adjustment	759	3,444
Balance at the end of the period <sup>3</sup>	131,300	125,775

1. Includes \$63.2 million (30 June 2023: \$59.6 million) of fair value adjustments from business combination in the year ended 30 June 2020.
2. Includes (\$0.8) million (30 June 2023: (\$1.2) million) of fair value adjustments from business combination in the year ended 30 June 2020.
3. Includes \$61.6 million (30 June 2023: \$63.2 million) of fair value adjustments from business combination in the year ended 30 June 2020.

#### Note 10: Litigation investments - purchased claims

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Balance at 1 July <sup>1</sup>	37,423	47,040
Interest revenue	1,182	5,122
Additions	12,432	-
Increase in carrying value	781	(16,387)
Carrying value disposed <sup>2</sup>	(94)	(651)
Impairment loss	(4,144)	(1,546)
Foreign currency adjustment	(136)	3,845
Balance at the end of the period <sup>3</sup>	47,444	37,423

At 31 December 2023, the fair value of the litigation investments - purchased claims amounted to \$47.4 million (30 June 2023: \$37.4 million) and the gross contractual amount was \$405.2 million (30 June 2023: \$169.0 million).

On 15 December 2023, Fund 6 acquired a portfolio of non-performing loans for a transaction price of \$12.4 million.

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
<b>Net loss on disposal of litigation investments - purchased claims</b>		
Proceeds	12	-
Carrying value disposed <sup>2</sup>	(94)	-
	(82)	-

1. Includes \$0.9 million (30 June 2023: \$0.6 million) of fair value adjustments from the business combination in the year ending 30 June 2020.
2. Includes \$nil (30 June 2023: \$0.2 million) of fair value adjustments from the business combination in the year ending 30 June 2020.
3. Include \$0.9 million (30 June 2023: \$0.9 million) of fair value adjustments from the business combination in the year ending 30 June 2020.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 11: Litigation investments - intangible assets

#### (a) Reconciliation of carrying amounts

The carrying value of litigation investments - intangible assets can be summarised as follows:

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
External funding costs	291,995	337,167
Capitalised overheads	58,187	49,143
Gross carrying amount at cost	350,182	386,310
Accumulated impairment	(45,028)	(16,225)
Net carrying amount	305,154	370,085

Included in the closing balance is \$17.7 million (30 June 2023: \$18.1 million) of purchase price adjustments that originally arose from business combination.

#### (b) Impairment testing of litigation investments - intangible assets

Except for specific litigation investments – intangible assets that are subject to an unfavourable judgement or award, the recoverable amount of each of the litigation investments – intangible assets is determined based on a value in use calculation using cash flow projections based on financial budgets approved by management for the expected length of each investment.

The following describes each key assumption on which management has based its cash flow projections when determining the value in use of litigation investments - intangible assets:

- The estimated cost to complete is budgeted based on estimates provided by the external legal advisors handling the litigation.
- The value to the Group, once completed, is estimated based on the successful conclusion and the resulting expected settlement or judgment amount of the litigation and the fees due to the Group under the litigation funding contract.
- The discount rate of 12% applied to the cash flow projections is based on the Group's weighted average cost of capital and other factors relevant to the particular investment including country risk.

At 31 December 2023, the balance of provisions for impairment was \$45.0 million (30 June 2023: \$16.2 million). The \$28.8 million net movement in the period reflects:

- \$31.9 million of new impairments in relation to 19 investments;
- the net impact of investment and the asset derecognised; and
- foreign exchange variances.

For new or increased impairments, during the impairment review, management have determined that either a successful outcome for the investment was no longer likely to occur or that the likely outcome would not recover the current carrying value of the investment. The discount rate used in the impairment indicator assessment of these assets was 12%. After taking into account the impairment indicators, at 31 December 2023, the 19 investments have a combined carrying value of \$13.8 million. This amount reflects the net recoverable amount expected to be received from the investments.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 12: Investment in associates

	Consolidated			
	Litigation Investments – Investment in Associates		Others	
	31-Dec-23	30-Jun-23	31-Dec-23	30-Jun-23
	\$'000	\$'000	\$'000	\$'000
Balance at 1 July	56,336	–	6,981	5,031
Additions (Note 23)	116,997	56,336	600	1,280
Adjustment	(6,650)	–	–	–
Share of (Loss)/Profit	(8,148)	–	(65)	555
Foreign currency adjustment	(1,587)	–	(83)	115
Balance at the end of the period	156,948	56,336	7,433	6,981

The above balances and movements includes secondary market sales that occurred including the Fund 1 sale in May 2023 and the partial sale of the US IP portfolio in the current period. On deconsolidation, OBL's residual interest within these entities are measured at the present value of probabilistic cash flows and subsequently accounted for under equity accounting. Refer to Note 23 for further information on the current period transaction.

The current period transaction resulted in a net gain on deconsolidation of subsidiaries amounted \$73.1 million, including a net gain from deconsolidation of Omni Bridgeway (Fund 4) Eagle SPV LLC of \$79.8 million (refer to Note 23) and an adjustment on initial recognition of Omni Bridgeway (Fund 1) LLC of \$6.7 million.

Included in "Others" is OB Capital Coop U.A, which is an associate of the Group and was acquired through the acquisition of Omni Bridgeway Holding B.V. in November 2019. The entity invests in litigation investments in the Netherlands. The Coop agreement outlines the various powers and rights of responsibilities of the members, includes provisions that provide the Group with significant influence over the entity.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### C. CAPITAL STRUCTURE

#### Note 13: Financial risk management

The value of the Group's financial assets and liabilities will be impacted by changes in interest rates and foreign exchange rates. The carrying amount of the financial assets and liabilities of the Group approximate their fair values.

##### Fair values

The carrying amounts of financial assets and liabilities of the Group carried at amortised cost approximate their fair values.

For the purposes of disclosure, the fair value measurements used for all assets and liabilities below are level 3.

	Carrying Amount		Fair Value	
	31-Dec-23	30-Jun-23	31-Dec-23	30-Jun-23
	\$'000	\$'000	\$'000	\$'000
<b>Financial assets</b>				
Receivables from litigation contracts and other	147,038	186,431	147,038	186,431
Litigation investments - purchased claims	47,444	37,423	47,444	37,423
Financial investments	13,895	7,078	13,895	7,078
Security deposits	3,019	2,925	3,019	2,925
	<b>211,396</b>	<b>233,857</b>	<b>211,396</b>	<b>233,857</b>
<b>Financial liabilities</b>				
Trade and other payables	48,041	50,110	48,041	50,110
Borrowings	182,616	181,639	182,616	181,639
Deferred consideration	2,984	4,074	2,984	4,074
Variable deferred consideration – business combination	9,513	14,773	9,513	14,773
Variable consideration – litigation investments - purchased claims	8,211	7,667	8,211	7,667
	<b>251,365</b>	<b>258,263</b>	<b>251,365</b>	<b>258,263</b>

##### Variable deferred consideration – business combination

The significant inputs used in the fair value measurements of deferred and variable deferred consideration – business combination, categorised within Level 3 of the fair value hierarchy, together with a quantitative sensitivity analysis as at 31 December 2023 are shown below:

Item	Valuation technique	Significant unobservable inputs	Range (weighted average)	Sensitivity of the input to fair value
Variable deferred consideration	Black Scholes Option Pricing Model	Exercise price	<b>Theoretical exercise price based on the floor price of \$3.407</b>	
		Volatility	<b>45% at 31 December 2023 and 40% at 30 June 2023</b>	<b>At 31 December 2023:</b> An absolute 5% increase in the volatility would result in a \$10,000 increase in the value of the liability. An absolute 5% decrease in the volatility would result in a \$6,000 decrease in the value of the liability.  At 30 June 2023: An absolute 5% increase in the volatility would result in a \$170,000 increase in the value of the liability. An absolute 5% decrease in the volatility would result in a \$164,000 decrease in the value of the liability.
		Underlying share price	<b>\$1.355 at 31 December 2023 and \$2.62 at 30 June 2023</b>	<b>At 31 December 2023:</b> A relative 5% increase in the share price would result in a \$6,000 increase in the value of the liability. A relative 5% decrease in the share price would result in a \$2,000 decrease in the value of the liability.  At 30 June 2023: A relative 5% increase in the share price would result in a \$176,000 increase in the value of the liability. A relative 5% decrease in the share price would result in a \$153,000 decrease in the value of the liability.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 13: Financial risk management (continued)

Item	Valuation technique	Significant unobservable inputs	Range (weighted average)	Sensitivity of the input to fair value
Variable deferred consideration (continued)	Black Scholes Option Pricing Model (continued)	Dividend yield	<b>At 31 December 2023:</b> <b>0% for 8-Nov-24 payment</b>  At 30 June 2023: 0% for 8-Nov-23 payment; 0% for 8-Nov-24 payment	<b>At 31 December 2023:</b> <b>An absolute 1% increase in dividend yield would result in a \$0 decrease in the value of the liability. An absolute 1% decrease in dividend yield would result in a \$0 increase in the value of the liability.</b>  At 30 June 2023: An absolute 1% increase in dividend yield would result in a \$33,000 decrease in the value of the liability. An absolute 1% decrease in dividend yield would not result in a change in value of the liability.
		Risk free rate	<b>At 31 December 2023:</b> <b>4.1% for 8-Nov-24 payment</b>  At 30 June 2023: 4.36% for 8-Nov-23 payment; 4.36% for 8-Nov-24 payment;	<b>At 31 December 2023:</b> <b>An absolute 0.5% increase in risk free rate would result in a \$27,000 decrease in the value of the liability. An absolute 0.5% decrease in risk free rate would result in a \$28,000 increase in the value of the liability.</b>  At 30 June 2023: An absolute 0.5% increase in risk free rate would result in a \$43,000 decrease in the value of the liability. An absolute 0.5% decrease in risk free rate would result in a \$41,000 increase in the value of the liability.
		FX forward rate (AUD/EUR)	<b>At 31 December 2023:</b> <b>8-Nov-24: 1.63</b>  At 30 June 2023: 8-Nov-23: 1.64 8-Nov-24: 1.66	<b>At 31 December 2023:</b> <b>A relative 5% increase/(decrease) in the forward exchange rates would result in a \$335,000 increase/(decrease) in the value of the liability.</b>  At 30 June 2023: A relative 5% increase/(decrease) in the forward exchange rates would result in a \$714,000 increase/(decrease) in the value of the liability.

### Note 14: Cash and cash equivalents

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Cash at bank	130,144	115,430
Short-term deposits	2,702	1,586
	<b>132,846</b>	117,016

Cash at bank earns interest based on available bank deposit rates. The carrying amounts of cash and cash equivalents represent fair value. Of the cash at bank, \$3.3 million (30 June 2023: \$2.2 million) is restricted.

Short-term deposits are made for varying periods depending on the immediate cash requirements of the Group. As at 31 December 2023, all short-term deposits maturity dates are less than 90 days from inception.

#### Bank guarantees

Bank guarantees have been issued by the Group's bankers as security for leases over premises and banking facilities. As at 31 December 2023, guarantees of \$1.8 million were outstanding (30 June 2023: \$1.7 million). The Group has a total guarantee facility limit of \$1.8 million (30 June 2023: \$1.7 million) that is secured by an offset arrangement with deposits of \$1.6 million (30 June 2023: \$1.5 million).

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 15: Borrowings

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
<b>Non-Current</b>		
Senior Facility	182,616	181,639
Borrowings - Fund 8	9,449	—
	<b>192,065</b>	181,639

The total amount of drawn down from debt facility at 31 December 2023 was \$190.0 million (30 June 2023: \$190.0 million). The facility terms include a variable rate of interest based on the BBSW Bid rate plus a fixed margin of 7.00% per annum, a maturity date of 1 July 2027.

During the half year ended 31 December 2023, Fund 8 entered into the first tranche of its debt capital with an investment vehicle owned by funds managed by affiliates of Fortress Investment Group for €135.0 million. Capital loss in Fund 8 is insured pursuant to a principal protection insurance indemnity of an initial amount of €135.0 million. The debt facility and the insurance provide for a four-year investment based on a commencement date of 21 August 2023. During the investment period and a subsequent four-year harvest period, all investment proceeds are applied against the outstanding debt balance. As of 31 December 2023, \$10.1 million were drawn down from Fund 8 debt facility.

The Group complied with the financial and non-financial covenants throughout the reporting period.

### Note 16: Contributed equity

Ordinary shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
<i>Contributed equity</i>		
Issued and fully paid ordinary shares	462,253	449,854

#### (a) Ordinary shares

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

	Consolidated			
	Period ended 31-Dec-23		Year ended 30-Jun-23	
	Number		Number	
	000	\$'000	000	\$'000
<b>Movement in ordinary shares</b>				
Balance at 1 July	278,619	449,854	268,639	406,963
Shares issued during the period (deferred and variable deferred consideration)	—	—	7,756	30,712
Shares issued upon exercise of performance rights	1,852	12,399	2,768	13,839
Share Buy-Back Scheme	—	—	(544)	(1,660)
Balance at period end	<b>280,471</b>	<b>462,253</b>	278,619	449,854

#### (b) Performance rights

At 31 December 2023, there were 12,421,755 unissued ordinary shares in respect of outstanding share performance rights (30 June 2023: 15,421,416).

#### (c) Variable deferred consideration shares

At 31 December 2023, there were 6,221,298 variable deferred consideration shares remaining to be issued (30 June 2023: 6,221,298).

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### D. WORKING CAPITAL, OTHER ASSETS AND OTHER LIABILITIES

#### Note 17: Trade and other receivables

Receivables are recognised initially at the present value of owed amount and subsequently remeasured at amortised cost using the effective interest rate method, less an allowance for any uncollectible amounts.

Receivables due from the completion of litigation investments are recognised upon various stages of completion of the underlying litigation in conjunction with the income recognition criteria of each investment. Collectability is reviewed on an ongoing basis and at each reporting period.

The Group recognises an allowance for expected credit losses (ECLs) for all receivables based on the difference between the contractual cash flows due and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

Other receivables comprise interest receivable upon the maturity of the Group's short-term deposits (between 30 and 90 days), receivables from co-funders of litigation contracts in progress, short term loans and deposits receivable.

	Consolidated	
	31-Dec-23 \$'000	30-Jun-23 \$'000
<b>Current</b>		
Receivables from litigation contracts	66,594	101,929
Other receivables	37,395	38,841
	<b>103,989</b>	<b>140,770</b>
<b>Non-current</b>		
Receivables from litigation contracts	43,044	43,769
Other receivables	5	1,892
	<b>43,049</b>	<b>45,661</b>

#### Fair value and credit risk

Due to the nature of these receivables, the carrying value of the current and non-current receivables approximates fair value. The maximum exposure to credit risk associated with receivables is the carrying value of receivables.

#### Note 18: Other assets

	Consolidated	
	31-Dec-23 \$'000	30-Jun-23 \$'000
<b>Current</b>		
Prepayments	7,099	5,075
Deposits	3,019	2,925
	<b>10,118</b>	<b>8,000</b>
<b>Non-current</b>		
Prepayments	13,630	16,988
Other	796	800
	<b>14,426</b>	<b>17,788</b>



# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 19: Other financial liabilities

Variable deferred consideration is valued at fair value at the acquisition date as part of a fair value through profit or loss business combination. It is subsequently remeasured at fair value at each reporting date.

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
<b>Current</b>		
Deferred consideration – insurance	931	1,099
Variable deferred consideration – business combination	9,513	6,998
	<b>10,444</b>	<b>8,097</b>
<b>Non-current</b>		
Deferred consideration – insurance	2,053	2,975
Variable deferred consideration – business combination	–	7,775
	<b>2,053</b>	<b>10,750</b>

The deferred consideration - insurance relates to insurance product acquired for Funds 2&3.

#### Variable deferred consideration - business combination

This relates to the acquisition of OBE Group. The determination of the fair value is designated as level 3 in the fair value hierarchy. Refer to Note 13 for further information.

The following table reconciles the movements in recurring fair value measurements categorised within level 3 of the fair value hierarchy:

	Deferred consideration – business combination <sup>1</sup>	Variable deferred consideration – business combination	Total
	\$'000	\$'000	\$'000
<b>Current</b>			
At 1 July 2023	–	6,998	6,998
Issue of shares / Payment of cash to satisfy the liability	–	(3,558)	(3,558)
Reclassification from non-current	–	6,115	6,115
Effect of movement in foreign currency	–	(42)	(42)
At 31 December 2023	–	<b>9,513</b>	<b>9,513</b>
<b>Non-current</b>			
At 1 July 2023	–	7,775	7,775
Fair value remeasurement recognised through profit or loss	–	(1,567)	(1,567)
Reclassification to current	–	(6,115)	(6,115)
Effect of movement in foreign currency	–	(93)	(93)
At 31 December 2023	–	–	–

	Deferred consideration – business combination <sup>1</sup>	Variable deferred consideration – business combination	Total
	\$'000	\$'000	\$'000
<b>Current</b>			
At 1 July 2022	15,491	13,670	29,161
Fair value remeasurement recognised through profit or loss	337	(1,161)	(824)
Issue of shares to satisfy the liability	(16,297)	(14,415)	(30,712)
Reclassification from non-current	–	8,503	8,503
Effect of movement in foreign currency	469	401	870
At 30 June 2023	–	<b>6,998</b>	<b>6,998</b>
<b>Non-current</b>			
At 1 July 2022	–	16,568	16,568
Fair value remeasurement recognised through profit or loss	–	(1,617)	(1,617)
Reclassification to current	–	(8,503)	(8,503)
Effect of movement in foreign currency	–	1,327	1,327
At 30 June 2023	–	<b>7,775</b>	<b>7,775</b>

1. Deferred consideration - business combination was fully paid via shares issue in December 2022.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 20: Provisions

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
<b>Current</b>		
Annual leave and vested long service leave	4,068	4,483
Adverse costs	27,259	26,753
Bonus	-	2
	<b>31,327</b>	<b>31,238</b>
<b>Non-current</b>		
Premises lease make good	621	626
Long service leave	516	665
	<b>1,137</b>	<b>1,291</b>

#### Annual leave and vested long service leave

Provision is made for employee benefits accumulated as a result of employees rendering services up to the end of the reporting period.

#### Bonus

The bonus provision relates to amounts accrued based on management's estimate to be paid to employees (including STIP).

#### Premises lease make good

The make good provision relates to amounts recognised for make good requirements on leases of office space.

### Note 21: Commitments and contingencies

Certain litigation funding agreements entered into by a Group entity contain an undertaking to pay any adverse costs awarded should the funded party's litigation be unsuccessful. Adverse costs is the name given to the legal costs of the successful party in applicable "cost shifting" jurisdictions, which generally excludes the United States of America. Based on past experience, an award for adverse costs to a defendant will approximate 40% to 80% (depending on the jurisdiction) of the amount paid by the claimant to pursue the litigation. In cases with multiple defendants, this range can be exceeded.

The Group assesses all of its investments for the probability of having to disburse adverse costs and, when deemed necessary, records the amount expected to pay out as a provision.

Certain Group entities mitigate the risk of paying adverse costs through after the event insurance ("ATE"). In addition, "top-up" ATE insurance may be obtained for single investments to reduce adverse cost concentration risk, and to provide for additional cover.

When the Group records a provision for adverse costs that is subject to ATE insurance, an insurance receivable is correspondingly recorded for the estimate of the coverage. The provisions and insurance receivable recorded are subject to estimates that take into account the portfolio effects, and in respect of the latter, the self-insured excess and the policy indemnity amount.

At 31 December 2023, the adverse cost exposure is \$27.3 million (with Fund 5 at 20%) (refer to Note 20). Of this provision \$8.3 million is expected to be recovered from insurance or a co-funding agreement.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### E. THE GROUP, MANAGEMENT AND RELATED PARTIES

#### Note 22: Related party disclosures

##### Transactions with related entities

The following table provides the total amount of transactions that were entered into with related parties for the relevant periods.

	Consolidated	
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Transactions with OB DARP Cooperatief UA <sup>1</sup>	62	724
	62	724

1. During the period, the Group received management fees from OB DARP Cooperatief UA, a related party of the Group.

##### Loans with a related entity

The following table provides the total amount of loans with related parties for the relevant financial period.

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Loans with Omni Bridgeway DARP Cooperatief UA	6,576	6,697
	6,576	6,697

#### Note 23: Composition of the Group

The Group's subsidiaries can be summarised as follows:

Name	Country of Incorporation	Percentage Owned	
		At 31-Dec-23 %	At 30-Jun-23 %
<b>Funds 2 &amp; 3</b>			
Omni Bridgeway (Fund 2) Pty Ltd	Australia	29	27
Omni Bridgeway (Fund 3) Pty Ltd	Australia	29	27
IMF Bentham ROW SPV 1 Limited	United Kingdom	29	27
IMF Bentham ROW SPV 2 Limited	Australia	29	27
<b>Fund 4</b>			
Omni Bridgeway (Fund 4) Invt 1 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 2 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 3 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 4 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 5 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 6 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 7 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 8 LP	USA	20	20
Omni Bridgeway (Fund 4) Invt 9 LP	USA	20	20
JPV I LP	USA	20	20
Omni Bridgeway (Fund 4) S2 L.P. <sup>1</sup>	USA	20	-
<b>Fund 5</b>			
Omni Bridgeway (Fund 5) GPA Pty Ltd	Australia	100	100

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 23: Composition of the Group (continued)

Name	Country of Incorporation	Percentage Owned	
		At 31-Dec-23 %	At 30-Jun-23 %
<b>Fund 6</b>			
Omni Bridgeway BV	Netherlands	81	81
Omni Bridgeway LegalTech BV	Netherlands	41	41
Omni Bridgeway Emerging Markets BV	Netherlands	81	81
Omni Bridgeway Collective Redress BV	Netherlands	81	81
Omni Bridgeway Asia Pte Ltd	Singapore	81	81
Omni Bridgeway Holding (Switzerland) SA	Switzerland	81	81
Omni Bridgeway SA	Switzerland	81	81
Omni Bridgeway GmbH	Germany	81	81
Omni Bridgeway France SAS	France	81	81
Omni Bridgeway Finance BV	Netherlands	81	81
Stichting Client Accounts Omni Bridgeway	Netherlands	N/A	N/A
Stichting Cartel Compensation	Netherlands	N/A	N/A
Stichting Trucks Cartel Compensation	Netherlands	N/A	N/A
Omni Bridgeway Italy S.r.L	Italy	81	81
FT Atlas I <sup>5</sup>	Morocco	N/A	N/A
<b>Fund 7</b>			
Omni Bridgeway Advisory Ltd	United Arab Emirates	65	65
<b>Fund 8</b>			
Omni Bridgeway (Fund 8) Guernsey Investments Ltd	Guernsey	81	81
Omni Bridgeway (Fund 8) Delaware SPV LLC <sup>2</sup>	USA	81	-
Omni Bridgeway (Fund 8) Guernsey SPV Limited <sup>3</sup>	Guernsey	81	-
Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 1 <sup>4</sup>	USA	81	-
Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 2 <sup>4</sup>	USA	81	-
Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 3 <sup>4</sup>	USA	81	-
<b>Group Subsidiaries</b>			
Omni Bridgeway Holdings (Fund 1) LLC	USA	100	100
Security Finance (Fund 4) LLC	USA	100	100
Omni Bridgeway Capital GP (Fund 4) LLC	USA	100	100
Omni Bridgeway (USA) LLC	USA	100	100
Omni Bridgeway Management (USA) LLC	USA	100	100
Omni Bridgeway Holdings (USA) Inc	USA	100	100
Security Finance LLC	USA	100	100
Omni Bridgeway Capital (Canada) Limited	Canada	100	100
Lien Finance Canada Limited	Canada	100	100
Omni Bridgeway (Singapore) Pte Limited	Singapore	100	100
Omni Bridgeway (UK) Limited	United Kingdom	100	100
Omni Bridgeway (Cayman) Limited	Cayman Islands	100	100
Omni Bridgeway (Storm) Holdings Pty Ltd	Australia	100	100
Omni Bridgeway (Storm) Holdings BV	Netherlands	100	100
Omni Bridgeway Investment Management Ltd	Australia	100	100
Omni Bridgeway Holding BV	Netherlands	100	100
Omni Bridgeway Investment BV	Netherlands	100	100
Omni Bridgeway (NZ) Limited	New Zealand	100	100
Crestwood I LLC	USA	100	100

1. Incorporated on 27 October 2023.

2. Incorporated on 21 July 2023.

3. Incorporated on 27 July 2023.

4. Incorporated on 31 July 2023.

5. The Moroccan securitization special purpose vehicle was founded during the period to setup a portfolio purchased by Omni Bridgeway S.A.

For all subsidiaries where there is less than 51% ownership interest, the Group has power to direct the relevant activities of the investee under contractual arrangements and exposure to variable returns the Group is considered to be acting as principal and thus has control.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 23: Composition of the Group (continued)

Movements in NCIs of material partly owned subsidiaries during the period were as follows:

	Consolidated				
	Fund 1 \$'000	Funds 2&3 \$'000	Fund 4 \$'000	Fund 6 \$'000	Total \$'000
Balance at 1 July 2022	73,219	112,784	91,013	133,593	410,609
Contributions	10,548	15,880	85,390	24,036	135,854
Distributions	(34,244)	(24,950)	(33,972)	-	(93,166)
Deconsolidation of Subsidiary	(49,518)	-	-	-	(49,518)
Change in share of net assets attributable to NCI	(4,076)	2,938	(3,662)	(2,356)	(7,156)
Profit	4,071	11,416	11,870	5,164	32,521
Other comprehensive income	-	250	3,687	2,354	6,291
Balance at 30 June 2023	-	118,318	154,326	162,791	435,435
Contributions	-	10,400	39,619	12,003	62,022
Distributions	-	(21,621)	(37,161)	-	(58,782)
Change in share of net assets attributable to NCI	-	1,851	5,300	685	7,836
Profit/(loss)	-	-	83,838	(2,854)	80,984
Other comprehensive loss	-	(89)	(4,999)	(684)	(5,772)
Balance at 31 December 2023	-	108,859	240,923	171,941	521,723

On 8 December 2023, the Group sold a 25% interest in a portfolio of 15 intellectual property (IP) investments in Fund 4 to an affiliate of GLS Capital Partners Fund II, LP for an initial amount of \$31.5 million. The transaction resulted in the deconsolidation of the Fund 4 entity, Omni Bridgeway (Fund 4) Eagle SPV LLC by the Group because of the loss of control on the transaction date.

The residual interest in the portfolio of \$116.7 million is recognised as an investment in associate within the Group Consolidated Financial Statements. An aggregate net gain to the Group of \$74.7 million was recognised into the profit or loss, including the effect of the derecognition of related capitalised overhead costs amounted \$5.1 million.

#### Deconsolidation of Omni Bridgeway (Fund 4) Eagle SPV LLC:

	\$'000
<b>Carrying value of Assets and Liabilities</b>	
Cash and cash equivalent	31,494
Intangible assets	62,989
Liabilities	(31,494)
<b>Total carrying value of net assets</b>	<b>62,989</b>
Cash consideration	31,708
Fair value of residual interest	116,997
Foreign exchange	(485)
Director costs and expenses	(5,432)
<b>Net gain on deconsolidation of subsidiary</b>	<b>79,799</b>
<b>Derecognition - capitalised overheads<sup>1</sup></b>	<b>(5,149)</b>
<b>Net gain on deconsolidation of subsidiary after derecognition of capitalised overheads</b>	<b>74,650</b>

1. The capitalised overhead costs in relation to the disposed entity were fully written off upon the deconsolidation, as part of the calculation of net gain on derecognition of litigation investments - intangible assets in the profit or loss.

# Notes to the Interim Financial Report

## for the half year ended 31 December 2023 (continued)

### Note 24: Events after the reporting date

In January 2024, we received a positive appeal decision relating to a Fund 4 investment, and in February 2024, we reached settlement in two Fund 5 investments for which we anticipate recognising, in aggregate, approximately \$29 million income in 2H24.

Except as disclosed in this report there have been no other subsequent events after the reporting date that are not included in the Group Consolidated Financial Statements.

For personal use only

## Directors' Declaration

I state that, in the directors' opinion:

- the financial statements and notes of Omni Bridgeway Limited and its controlled entities (the Group) comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements
- the financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2023 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001, on behalf of the directors.



Michael Kay

Non-Executive Chairman

28 February 2024

## INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Omni Bridgeway Limited

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the half-year financial report of Omni Bridgeway Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2023, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (i) Giving a true and fair view of the Group's financial position as at 31 December 2023 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

#### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

#### Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.





### **Auditor's responsibility for the review of the financial report**

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2023 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**BDO Audit (WA) Pty Ltd**

BDO  


**Glyn O'Brien**

**Director**

Perth, 28 February 2024

For personal use only

## Corporate Information

This Interim Financial Report covers Omni Bridgeway Limited and its subsidiaries. The Group's functional and presentation currency is AUD (\$).

### Directors

Michael Kay	Non-Executive Chairman
Andrew Saker	Managing Director & CEO (retired 26 October 2023)
Raymond van Hulst	Managing Director & CEO (appointed 26 October 2023), former Executive Director and Co-Chief Investment Officer – EMEA
Karen Phin	Non-Executive Director
Christine Feldmanis	Non-Executive Director
Michael Green	Non-Executive Director

### Joint Company Secretaries

Jeremy Sambrook  
Christopher Huish

### Registered office and principle place of business in Australia

Level 7, 35 Clarence Street  
Sydney NSW 2000

Phone: +61 2 8223 3567  
Fax: +61 2 8223 3555

### Solicitors

**DLA PIPER**  
Level 9, 480 Queen Street  
Brisbane QLD 4000

**THOMSON GEER**  
Level 27, Exchange Tower 2 The Esplanade  
Perth WA 6000

### Share Registry

**COMPUTERSHARE**  
Level 11, 172 St Georges Terrace  
Perth WA 6000

### Auditors

**BDO AUDIT (WA) PTY LTD**  
Level 9  
Mia Yellagonga Tower 2 5 Spring Street  
Perth WA 6000

### Bankers

**NATIONAL AUSTRALIA BANK LIMITED**  
2 Carrington Street  
Sydney NSW 2000

**WESTPAC BANKING CORPORATION**  
275 Kent Street,  
Sydney NSW 2000

### Internet Address

[www.omnibridgeway.com](http://www.omnibridgeway.com)

The Company is listed on the Australian Securities Exchange with Sydney, Australia as its home exchange. Its ASX code is "OBL" and its shares were trading as at the date of this report.

### US ownership restriction

The ordinary shares of Omni Bridgeway are subject to ownership restrictions applying to residents of the United States. For further information, see the Investor section of our website or [omnibridgeway.com/investors/us-ownership-restriction](http://omnibridgeway.com/investors/us-ownership-restriction).

## Glossary

<b>AASB</b>	Australian Accounting Standards Board.
<b>CAGR</b>	Compound annual growth rate.
<b>EMEA</b>	The geographic region incorporating Europe, Middle East and Africa where the Group invests and offers its products and services.
<b>EPS</b>	Earnings per share.
<b>Estimated Portfolio Value (EPV)</b>	<p>OBL's estimate of the value that may be achieved from an investment's underlying litigation from time-to-time. For an investment where the funding entity earns:</p> <ol style="list-style-type: none"> <li>a percentage of the resolution proceeds arising from the underlying litigation or enforcement as a funding commission, EPV is the estimate of the investment's recoverable amount after considering the perceived capacity of the defendant to meet the claim and any other pertinent factors. Such amount is not necessarily the amount being claimed, nor is it an estimate of the return to the Group if the investment is successful. It includes the amount to the funded client and to the Group. It does not include co-funder portion</li> <li>a funding commission calculated as a multiple of the capital deployed; EPV is arrived at by taking the estimated potential income from the investment to the funding entity and grossing this up to an EPV using the Long-Term Conversion Rate at the time estimation. It does not include co-funder portion, or</li> <li>a funding commission calculated on a combination of the above bases or on an alternative basis, arriving at the EPV may utilise one of the above methodologies, or a hybrid construct, or an alternative methodology depending upon the components of the funding commission.</li> </ol> <p>OBE Group's EPV has been estimated on a conceptually consistent basis noting that, enforcement case investments may have a multi-layered approach from a timing and value perspective.</p> <p>Regardless of how calculated, an EPV is an estimate and is subject to change over time for a number of reasons, including, but not limited to, changes in circumstances and knowledge relating to an investment or the defendant(s) perceived capacity to meet the claim, partial recovery and, where applicable, ability to enforce or recover.</p> <p>Possible EPVs are reviewed and updated where necessary.</p>
<b>IFRS</b>	International Financial Reporting Standards.
<b>LTIP</b>	Long-Term Incentive Plan.
<b>NCI</b>	<p>Non-controlling interest.</p> <p>This represents the interests of external Fund investors in funds that are consolidated within the Group, in accordance with each of the respective Funds' return waterfall.</p>
<b>OBE Group</b>	Omni Bridgeway Holdings BV and subsidiary; it includes Fund 6 and Fund 7.
<b>OBL</b>	Omni Bridgeway Limited (ABN 45 067 298 088).
<b>STIP</b>	Short Term-Incentive Program.
<b>TSR</b>	Total shareholder return.

**Non-IFRS financial information included in this Report has been prepared in accordance with ASIC Regulatory Guidance 230 – Disclosing Non-IFRS financial information, issued December 2011. This information has not been audited or reviewed.**

### Disclaimer

None of the content in the Omni Bridgeway Limited ("OBL") Interim Financial Report is an offer to sell, or a solicitation of an offer to buy, any securities of OBL or any other company affiliated with OBL. In addition, nothing herein should be construed as an offer to buy or sell, nor a solicitation of an offer to buy or sell, any security or other financial instrument, or to invest assets in any account managed or advised by OBL or its affiliates. This Interim Financial Report is for the use of OBL's public shareholders and is not an offering of any OBL private fund.

## Americas

### Chicago

+1 872 260 2057  
500 West Madison Street  
Suite 1000  
Chicago IL 60661  
United States

### Dallas

+1 212 488 5331  
United States

### Houston

+1 713 965 7919  
LyondellBasell Tower  
1221 McKinney Street  
Suite 2860  
Houston TX 77010  
United States

### Los Angeles

+1 213 550 2687  
555 W. Fifth Street  
Suite 3310  
Los Angeles CA 90013  
United States

### Miami

+1 786 891 2228  
2 South Biscayne Blvd.  
Suite 3200  
Miami FL 33131  
United States

### Minneapolis

+1 612 488 9211  
60 South 6th Street  
Suite 2800  
Minneapolis MN 55402  
United States

### New York

+1 212 488 5331  
437 Madison Avenue  
36th Floor  
New York NY 10022  
United States

### San Francisco

+1 415 231 0363  
50 California Street  
Suite 2930  
San Francisco CA 94111  
United States

### Washington, D.C.

+1 212 488 5331  
2101 L Street, N.W.  
Suite 925  
Washington, D.C. 20037  
United States

### Montreal

+1 514 257 6971  
60 rue St-Jacques  
Bureau 401  
Montréal QC H2Y 1L5  
Canada

### Toronto

+1 416 583 5720  
250 The Esplanade  
Suite 127  
Toronto ON M5A 1J2  
Canada

### Montevideo

+1 514 257 6971  
Uruguay

## Asia-Pacific

### Melbourne

+61 3 9913 3301  
Level 3  
Bourke Place  
600 Bourke Street  
Melbourne VIC 3000  
Australia

### Perth

+61 8 9225 2300  
Level 10  
66 St Georges Terrace  
Perth WA 6000  
Australia

### Sydney

+61 2 8223 3567  
Level 7  
35 Clarence Street  
Sydney NSW 2000  
Australia

### Hong Kong

+852 3978 2629  
11/F Tower 2  
Admiralty Centre  
18 Harcourt Rd, Admiralty  
Hong Kong

### Singapore

+65 6813 2647  
Level 13-03  
6 Battery Road  
Singapore 049909

### Auckland

+64 21 990 620  
Level 2  
1 Albert Street  
Auckland 1010  
New Zealand

## Europe, Middle East & Africa

### Amsterdam

+31 70 338 4343  
Schiphol Boulevard 121  
1118 BG Schiphol  
Amsterdam  
The Netherlands

### Cologne

+49 221 801155-0  
Gereonstr. 43-65  
50670 Cologne  
Germany

### Geneva

+41 22 818 6300  
Rue de la Rôtisserie 4  
1204 Geneva  
Switzerland

### London

+44 203 968 6061  
Link House  
78 Cowcross Street  
London EC1M 6EJ  
United Kingdom

### Madrid

+31 70 338 4343  
Spain

### Milan

+39 339 448 3907  
Via Fatebenefratelli, 5  
20121 Milano MI  
Italy

### Paris

+33 6 5159 4359  
31 rue du Colisée  
75008 Paris  
France

### Dubai

+971 4 514 4608  
Unit 1905, Level 19  
Index Tower  
Dubai International  
Financial Centre  
507152 Dubai  
United Arab Emirates